Literature DB >> 23519263

Hydroxysafflor yellow A (HSYA) from flowers of Carthamus tinctorius L. and its vasodilatation effects on pulmonary artery.

Yuhua Bai1, Ping Lu, Chenghua Han, Chunyue Yu, Minggang Chen, Fa He, Dan Yi, Lijun Wu.   

Abstract

Flowers of Carthamus tinctorius L. are traditionally used in China to treat cerebrovascular and cardiovascular diseases. Hydroxysafflor yellow A (HSYA), the main constituent of Carthamus tinctorius L. flowers, is known for its multiple biological activities. In the present study, HSYA was isolated from Carthamus tinctorius L. flowers by a macroporous resin adsorption chromatography method coupled with a Waters high-throughput auto-purification system and it's vasodilatation effects on pulmonary artery (PA) were explored by an assay of tension study on rat pulmonary artery (PA) rings. Results suggest that HSYA possesses vascular relaxation effects on rat PA by activating the KV channel in pulmonary vascular smooth muscle cells (PVSMCs).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23519263      PMCID: PMC6268686          DOI: 10.3390/molecules171214918

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


1. Introduction

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increased pulmonary vascular resistance, leading to chronic elevation in pulmonary arterial pressure resulting from restricted flow through the pulmonary arterial circulation system. These pathobiological features typically lead to right-side heart failure and premature death [1,2]. Although available treatments can improve prognosis, this disease has been considered incurable and with poor survival [3,4]. Treatments for PAH have evolved in the last decade because of a greater understanding of the disease pathology, as well as increased availability of medications targeting known affected pathways, but application of these medications is constricted owing to their serious side effects, which are hard to overcome. For example, the side effects of endothelium receptor antagonists include potential for hepatotoxicity, anemia, and edema [5], those of phosphodiesterase inhibitors include headaches, epistaxis, flushing, and dyspepsia [6]; moreover, most prostanoids are pharmacologically unstable, and adverse effects of their subcutaneous administration include pain or erythema at the site. Other common side effects include headache, nausea, rash, and diarrhea [7]. The conventional therapies have never been proven to be beneficial in a randomized, prospective manner. Accordingly, new alternative treatments of PAH are currently being explored, especially those derived from herbal plants which may possess diverse bioactivities. Carthamus tinctorius L. is a kind of therophyte belonging to the Dicotyledoneae subclass, Compositae family [8]. Flowers of Carthamus tinctorius L. are used extensively in traditional Chinese medicine for the treatment of cerebrovascular and cardiovascular diseases [9,10,11]. 2,4-di-β-d-glucopyranosyl-3,4,5-trihydroxy-6-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propenyl]-2,5-cyclohexadien-1-one (HSYA, Figure 1), the major bioactive compound of Carthamus tinctorius L., has been shown to antagonize platelet-activating factor receptor binding [12] and reduce myocardial infarct size [13]. Hypotensive and anti-thrombotic activities and inhibitory effects on platelet aggregation have also been reported [14,15]. It was also reported that HSYA significantly reduces blood pressure and heart rate [16], protects HUVECs (Human Endothelial Cells from Umbilical Cords) from hypoxia-induced injuries by inhibiting cell apoptosis and cell cycle [17]. Moreover, HSYA caused a concentration-dependent anti-contraction effects by KC l or PE in endothelium-intact and endothelium-denuded aortic rings [18]. However, there has been no report on the effects of Carthamus tinctorius L. and HSYA on pulmonary artery, so in the present study we explore the vasodilatation effects of HSYA on rat pulmonary artery and its potential mechanism.
Figure 1

The chemical structure of HSYA.

2. Results and Discussion

2.1. HPLC Chromatography of F2 from Carthamus tinctorius L. Crude Extract and Separated HSYA

In order to get good resolution of adjacent peaks within a short analysis time, the optimum HPLC conditions were tested. In the beginning, various mixtures of water-methanol and acetonitrile-water were selected as mobile phase in the analysis of the fractions from Carthamus tinctorius L. separated by a D101 macroporous resin column, but the separation was not satisfactory. Thus 0.2% formic acid was added to ensure a better separation. The results indicated that when the methanol- formic acid in water (0.2%) and acetonitrile were used as mobile phase (wateracetonitrilemethanol = 62:2:36) in isocratic mode, major peaks showed a good separation. The HPLC chromatograph of the F2 is shown in Figure 2. HPLC chromatograph of separated HSYA obtained under the same HPLC conditions as the above is shown in Figure 3. The structure of the separated HSYA was further confirmed by IR, NMR and positive ESI-MS data.
Figure 2

The HPLC chromatograph of the second fraction (F2) of crude extract from Carthamus tinctorius L. flowers obtained from a macroporous resin column. Conditions: column: ODS C18 (250 mm × 4.6 mm I.D., 5 μm); mobile phase: 0.2% formic acid in water (A), acetonitrile (B) and methanol (C) (A:B:C = 62:2:36) in isocratic elution mode for 30 min. The flow rate was 1 mL/min, aliquots of 10 µL were injected and the absorbance was recorded at 403 nm.

Figure 3

HPLC chromatograph of the separated HSYA. Conditions: same as Figure 2.

2.2. Effects on PA Rings

2.2.1. Effect of HSYA (10−9–10−5 M) on PE-Induced Vascular Constriction

To determine the vascular effects of HSYA on rat pulmonary artery rings, we tested different concentrations of HSYA (10−9–10−5 M). HSYA (10−9 M, 10−8 M, 10−7 M, 10−6 M, 10−5 M) was added to the bath and incubated for 30 min. After 30–40 min equilibration with a 0.3 g pre-load, the PA rings were then exposed to phenylephrine with a concentration gradient from 10−9 M–10−5 M and the data recorded. Results are shown in Figure 4A,B.
Figure 4

Vascular effect of HSYA on PE-induced constriction in rat PA rings with different concentration (10−9 M–10−5 M). * p < 0.05 compared with control; ** p < 0.01 compared with control.

2.2.2. Effect on Endothelium-Intact PA Rings

To determine the vascular effects of HSYA on rat pulmonary artery rings, endothelium-intact PA rings were studied in these experiments. As shown in Figure 5A, HSYA (10−5 M) had no effects on the rest tone of the rings. However, after 30 min incubation with HSYA and 30–40 min equilibration with a 0.3 g pre-load, the PA rings were then exposed to phenylephrine with a concentration gradient from 10−9 M–10−5 M. The exposure produced rapid contraction of these rings by 0.02–0.28 g and 0.05–0.4 g compared with control. The peak contraction was reached in 25 min and maintained for at least 30 min without evident decline. HSYA (10−9 M to 10−5 M) elicited a vasodilatation effect on the phenylephrine-induced restriction of artery rings (data was not shown). Basal tension of 0.3 g (passive force) was regarded as 100%. These results suggest that HSYA is effective at resisting PE-induced vascular constriction and this effect is HSYA concentration-dependent.
Figure 5

Vascular effect of HSYA on rat PA rings. (A) Vascular effect of HSYA on PE-induced vascular constriction in endothelium-intact rat PA rings; (B) Vascular effect of HSYA on PE-induced vascular constriction in endothelium-denuded rat PA rings. ** indicates the result has statistical significance (p < 0.01, compared with Normal). ## p < 0.01 compared with PE.

2.2.3. Effect on Endothelium-Denuded PA Rings

Using the same experimental procedure as above, vasorelaxing effects on endothelium-denuded PA rings were studied and the result was as shown in Figure 5B. The exposure produced a rapid contraction of these rings by 0.02–0.30 g and 0.03–0.50 g compared with control. Results indicate that HSYA is effective in resisting PE-induced vascular constriction and this effect is HSYA concentration-dependent. From the above experimental data, we can draw the conclusion that the vasorelaxing effect of HSYA has no relation with the PA endothelium.

2.2.4. Effect on PA Rings after Blocking K+ Channels of PVSMCs

The experimental procedure was the same as in 2.2.1, but before adding HSYA, the different K+ channel blockers glibenclamide (GLYB, KATP channel blocker), 4-Aminopyridine (4-AP, Kv channel blocker), Bacl2 (KIR channel blocker) and tetraethylammonium (TEA, a non-selective kv channel blocker) were added and incubated for 30 min, respectively. As shown in Figure 6A–E, the results suggest that the vascular relaxation effect of HSYA is significantly dependent on the Kv channels of PVSMCs.
Figure 6

Vascular effect of HSYA after blocking K+ channels of PVSMCs. (A) Vascular effect of HSYA after pretreatment with GLYB; (B) Vascular effect of HSYA after pretreatment with 4-AP; (C) Vascular effect of HSYA after pretreatment with Bacl2; (D) Vascular effect of HSYA after pretreatment with TEA; (E) Bar graph shows the vascular effect of HSYA after blocking the different K+ channels of PVSMCs. ** indicates the result has statistical significance (p < 0.01, compared with Control). ## p < 0.01 compared with HSYA.

3. Experimental

3.1. Apparatus

The separation instrument employed in the present study was a Waters 2545 high throughput preparation and purification system coupled with a UV detector (Waters Corporation, Milford, PA, USA), an ODS C18 column (250 mm × 19 mm I.D., 5 μm); The HPLC equipment was an Agilent 1200 HPLC system including a G1311A Quat-pump, a G1315D UV-vis photodiode array detector, a G1329A auto-sampler, a G1322A degasser and Angilent HPLC workstation (Agilent Technologies, Waldbronn, Germany). The nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance 300 spectrometer (Bruker Company, karlsruhe, Germany). Mass spectra were recorded on a Waters LCT-Premier spectrometer (Waters Corporation, Milford, PA, USA) in ESI ionization mode (positive). FTIR-8400S(SHIMADZU CORPORATION, Kyoto, Japan). Tension data acquisition was facilitated by using the CODAS software (Shanghai Alcott Biotech Co, Ltd., Shanghai, China), which allows waveform playback and analysis. Each PA ring was mounted on a force transducer (ALC-MPA, Shanghai Alcbio Biology Technology Co., Ltd., Shanghai, China) and placed in a water-jacketed organ bath. The system allows simultaneous recordings from eight rings.

3.2. Reagents and Materials

All organic solvents used for the preparation of crude sample and HPLC separation were of analytic grade (Guangcheng Chemical Factory; Tianjin; China). Methanol and acetonitrile used for HPLC analysis was of chromatographic grade (Yuwang Chemical Factory; Yucheng, China). HPLC-grade water was purified using a Milli-Q system (Millipore, Bedford, MA, USA). Phenylephrine was obtained from Sigma Chemical Co. (St. Louis, MO, USA). All other reagents were from common commercial sources. Flowers of Carthamus tinctorius L. were purchased from China National Pharmaceutical Group Corporation (Beijing, China) and air dried. The plant was authenticated by professor Donghua Wei of Harbin Medical University; and identified by comparison to a fully registered specimen (voucher number: 20110905) following the Chinese National Pharmacopoeia; kept at the herbarium of pharmacy college of Harbin Medical University-Daqing.

3.3. Plant Extract Preparation and Isolation of HSYA

The fresh flowers of Carthamus tinctorius L. (2 kg) were shade dried and powdered, then extracted three times at 60 °C for 30 min in distilled water (20 L). After removal of the solvent by evaporation under reduced pressure, the residue was dissolved in 10% ethanol (1,000 mL), then evaporated to dryness under vacuum to afford a residue (72.3 g), which was subjected to D101 macroporous resin column chromatography (200 g) using water-methanol step-gradient elution (100: 0–90: 10–80: 20–40: 60–0: 100, v/v) to yield five fractions F1–F5. The fraction F2 (2.8 g) was subjected to separation on a Waters 2545 high throughput preparation and purification system at 25 °C, using methanolacetonitrile–formic 0.2% in water (36:2:62) as mobile phase in isocratic elution mode. The flow-rate of the mobile phase was 17 mL/min. the effluents were monitored at 403 nm by UV detector and collected automatically to get HSYA (1.32 g). Structure identification was performed by nuclear magnetic resonance, mass spectrometry and infrared spectroscopy. Orange needle-like crystals, mp 184.2 °C. IR (KBr, cm−1): 3384, 2928, 1625, 1605, 1519, 1426. HR-ESI-MS (m/z): 611.1450, (C27H31O16). 1H-NMR: (DMSO-d6, 300 MHz):18.13 (1H, s, 3-OH), 10.05 (1H, s, 5-OH), 7.75 (1H, d, J = 15 Hz, H-8), 7.52 (1H, d, J = 15 Hz, H-9), 7.55 (1H, d, H-11), 6.83 (2H, d, J = 9 Hz, 12, H-14), 7.42 (2H, d, J = 9 Hz, 11, H-15), 3.91 (1H, d, J = 9.5 Hz, H-l’), 3.54 (1H, d, H-2’), 2.50 (1H, m, H-4’), 3.80 (1H, m, H-6’), 4.23 (1H, d, J = 9.5Hz, H-l’’), 4.10 (1H, m, H-2’’), 3.18 (1H, m, H-3’’), 3.12 (1H, m, H-4’’), 3.42 (1H, d, H-6’’). 13C-NMR (DMSO-d6, 100 MHz): 190.3 (s, C-l), 105.3 (s, C-2), 195.6 (s, C-3), 87.0 (s, C-4), 181.0 (s, C-5), 90.2 (s, C-6), 183.7 (s, C-7), 119.4 (s, C-8), 144.0 (s, C-9), 128.7 (s, C-10), 130.0 (d, C-11, 15), 117.3 (d, C-12, 14), 157.8 (s, C-13), 87.2 (d, C-l’), 72.0 (d, C-2’), 77.0 (d, C-3’), 71.3 (d, C-4’), 80.5 (d, C-5’), 62.6 (t, C-6’), 74.7 (d, C-l’’), 67.5 (d, C-2), 79.5 (d, C-3’’), 70.1 (d, C-4’’), 81.3(d, C-5’’), 63.7 (t, C-6’’). The 1H-NMR and 13C-NMR data were compared with the data given in literature [19], and the product thus confirmed to be HSYA.

3.4. Animals

Adult Wistar rats of either sex (150–200 g) were used in the studies accredited by the Institutional Animal Care and Use Committee (IACUC) of Harbin Medical University. The rats were housed in the Animal Research Center at a controlled ambient temperature of 22 ± 2 °C with 50 ± 10% relative humidity and a 12-h light-dark cycle (lights on at 8:00 AM). Standard rat chow and water were provided ad libitum to all rats. After the rats were deeply anesthetized with an intraperitoneal injection of 1% chloral hydrate according to their weight, PAs were carefully dissected from adult rats and cut into 3-mm-length rings under a dissecting microscope, maintained in cold Krebs solution containing (in mM) NaCl 127, KCl 4.7, NaHCO3 17, MgSO4 1.17, KH2PO4 1.18, CaCl2 2.5, and D-glucose 5.5 (pH 7.4, at 37 °C). In the case of endothelium-denuded preparations, the vessels were mechanically rubbed by a wolfram wire before equilibration. Endothelial integrity was examined in all experiments by the presence of the characteristic relaxation response to carbamyl choline chloride (5 × 10−6 M). After equilibration, each ring was contracted with 10−6 M PE followed by treatment with carbamyl choline chloride. Vascular rings displaying less than 10% relaxation to carbamyl choline chloride were considered as endothelium-denuded.

3.5. Tension Studies of Pulmonary Arterial (PA) Rings

Each PA ring was mounted on a ALC-MPA force transducer and placed in a water-jacketed organ bath. The system allows simultaneous recordings from eight rings. The rings were bathed with 3 mL oxygenated Krebs solution. PA rings were equilibrated under 0.3 g passive tension for 30 min. All rings were contracted with 1.0 mmol/L phenylephrine (PE) to ensure tissue vitality at the end of the experiment. Rings which did not exhibit a doubling of tension to PE were excluded from analysis. To study the vasorelaxation properties of HSYA in the PA rings with and without endothelium, the rings were pre-incubated with HSYA (10−9–10−5 M respectively) for 40 min, then cumulative concentration-response curves to PE were produced by adding increasing concentrations of PE (10−9 to 10−5 M) at 5-min internal, and examining the effects of HSYA.

3.6. Statistical Analysis

The experimental data are expressed as means ± SEM. Statistical analysis was performed with one-way ANOVA followed by Dunnett’s test where appropriate. p < 0.05 was considered statistically significant.

4. Conclusions

It may be concluded that Carthamus tinctorius L. flower shows pulmonary vascular relaxation effects. Our studies show that HSYA, the main constituent of Carthamus tinctorius L. flowers, exhibits strong effects against the vascular contractile response of PE. Finally we conclude that HSYA may be a potential pulmonary vascular relaxant for the treatment of pulmonary hypertension diseases like PAH, and it’s underlying mechanism is independent of PA endothelium, and it contributes to the function of pulmonary vascular smooth muscles (PVSMs), HSYA reduces the vascular tension through activating the Kv channel of PVSMCs, so it may be a potential medication for PAH.
  16 in total

1.  Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction.

Authors:  J M Post; J R Hume; S L Archer; E K Weir
Journal:  Am J Physiol       Date:  1992-04

2.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

3.  Hydroxysafflor yellow A protects rat brains against ischemia-reperfusion injury by antioxidant action.

Authors:  Xinbing Wei; Huiqing Liu; Xia Sun; Fenghua Fu; Xiumei Zhang; Jin Wang; Jie An; Hua Ding
Journal:  Neurosci Lett       Date:  2005-09-23       Impact factor: 3.046

4.  Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

Authors:  Raymond L Benza; Dave P Miller; Mardi Gomberg-Maitland; Robert P Frantz; Aimee J Foreman; Christopher S Coffey; Adaani Frost; Robyn J Barst; David B Badesch; C Gregory Elliott; Theodore G Liou; Michael D McGoon
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

5.  Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaïci; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Vincent Cottin; Bruno Degano; Xavier Jaïs; David Montani; Rogério Souza; Gérald Simonneau
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

Review 6.  Diagnosis and differential assessment of pulmonary arterial hypertension.

Authors:  Robyn J Barst; Michael McGoon; Adam Torbicki; Olivier Sitbon; Michael J Krowka; Horst Olschewski; Sean Gaine
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

7.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

8.  Effect of Hydroxysafflor yellow A on human umbilical vein endothelial cells under hypoxia.

Authors:  Deng Bo Ji; Li Yun Zhang; Chang Ling Li; Jia Ye; Hai Bo Zhu
Journal:  Vascul Pharmacol       Date:  2008-11-28       Impact factor: 5.773

9.  Two new quinochalcone yellow pigments from Carthamus tinctorius and Ca2+ antagonistic activity of tinctormine.

Authors:  M R Meselhy; S Kadota; Y Momose; N Hatakeyama; A Kusai; M Hattori; T Namba
Journal:  Chem Pharm Bull (Tokyo)       Date:  1993-10       Impact factor: 1.645

10.  [Ca2+]i inhibition of K+ channels in canine pulmonary artery. Novel mechanism for hypoxia-induced membrane depolarization.

Authors:  J M Post; C H Gelband; J R Hume
Journal:  Circ Res       Date:  1995-07       Impact factor: 17.367

View more
  10 in total

1.  Hydroxysafflor yellow A inhibits lipopolysaccharide-induced proliferation and migration of vascular smooth muscle cells via Toll-like receptor-4 pathway.

Authors:  Guoshuai Yang; Xiaoyan Zhou; Tao Chen; Yidong Deng; Dan Yu; Suyue Pan; Yanmin Song
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 2.  Anti-Hypertensive Herbs and Their Mechanisms of Action: Part II.

Authors:  M Akhtar Anwar; Sara S Al Disi; Ali H Eid
Journal:  Front Pharmacol       Date:  2016-03-08       Impact factor: 5.810

3.  Hydroxysafflor Yellow A Suppresses Platelet Activating Factor-Induced Activation of Human Small Airway Epithelial Cells.

Authors:  Xinjing Guo; Meng Zheng; Ruiyan Pan; Baoxia Zang; Ming Jin
Journal:  Front Pharmacol       Date:  2018-08-03       Impact factor: 5.810

4.  Neuroprotection of hydroxysafflor yellow A in experimental cerebral ischemia/reperfusion injury via metabolic inhibition of phenylalanine and mitochondrial biogenesis.

Authors:  Suning Chen; Mao Sun; Xianghui Zhao; Zhifu Yang; Wenxing Liu; Jinyi Cao; Yi Qiao; Xiaoxing Luo; Aidong Wen
Journal:  Mol Med Rep       Date:  2019-02-15       Impact factor: 2.952

Review 5.  Chemical and biological properties of quinochalcone C-glycosides from the florets of Carthamus tinctorius.

Authors:  Shijun Yue; Yuping Tang; Shujiao Li; Jin-Ao Duan
Journal:  Molecules       Date:  2013-12-10       Impact factor: 4.411

6.  Hydroxysafflor Yellow A inhibits the viability and migration of vascular smooth muscle cells induced by serum from rats with chronic renal failure via inactivation of the PI3K/Akt signaling pathway.

Authors:  Changliang Huo; Li Wang; Qiuli Wang; Yanbo Yang; Bo Chen
Journal:  Exp Ther Med       Date:  2021-06-08       Impact factor: 2.447

Review 7.  Natural Products to Counteract the Epidemic of Cardiovascular and Metabolic Disorders.

Authors:  Birgit Waltenberger; Andrei Mocan; Karel Šmejkal; Elke H Heiss; Atanas G Atanasov
Journal:  Molecules       Date:  2016-06-22       Impact factor: 4.411

8.  Protective effect of hydroxysafflor yellow A against acute kidney injury via the TLR4/NF-κB signaling pathway.

Authors:  Juan Bai; Jinyi Zhao; Dongxiao Cui; Fan Wang; Ying Song; Lianghua Cheng; Kai Gao; Jin Wang; Long Li; Shujun Li; Yanyan Jia; Aidong Wen
Journal:  Sci Rep       Date:  2018-06-15       Impact factor: 4.379

Review 9.  Hydroxysafflor Yellow A: A Promising Therapeutic Agent for a Broad Spectrum of Diseases.

Authors:  Hui Ao; Wuwen Feng; Cheng Peng
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-25       Impact factor: 2.629

10.  Huo Xue Tong Luo capsule, a vasoactive herbal formula prevents progression of asymptomatic osteonecrosis of femoral head: A prospective study.

Authors:  Qiu-Shi Wei; Guo-Ju Hong; Ying-Jia Yuan; Zhen-Qiu Chen; Qing-Wen Zhang; Wei He
Journal:  J Orthop Translat       Date:  2018-12-21       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.